About Highnoon
Highnoon is a company based in Lahore (Pakistan) founded in 1984. It operates as a B2B and D2C. Highnoon offers products and services including Feripro Capsule, Cardiology Products, and Gastroenterology Products. Highnoon operates in a competitive market with competitors including Eurofins Scientific, WuXi AppTec, Ipsen, CHEPLAPHARM and ANI Pharmaceuticals, among others.
- Headquarter Lahore, Pakistan
- SectorsHealthcare
- Website category Health · Pharmacy
- Email••••••••
- Website highnoon-labs.com
- Social LinkedIn Facebook Instagram
- Legal Name Highnoon Laboratories Limited
- Annual Revenue$27.71 B12.44as on Dec 31, 2025
- Net Profit$4.13 B21.83as on Dec 31, 2025
- EBITDA$6.81 B26.32as on Dec 31, 2025
Products & Services of Highnoon
Highnoon offers a comprehensive portfolio of products and services, including Feripro Capsule, Cardiology Products, and Gastroenterology Products.
Treats iron overload in thalassemia patients through donation programs.
Medicines for heart-related conditions in various therapeutic areas.
Formulations for gastrointestinal disorders and treatments.
People of Highnoon
28 people are tracked at Highnoon (11 in leadership, 5 in board & advisors, 12 in team).
| Name | Role | Group |
|---|---|---|
Adeel Abbas | CEO | Leadership |
Nael Najam | Director | Leadership |
Dr. Abida Perveen | Ass. Director Group Quality Compliance | Leadership |
Dr. Muhammad Saqlain Tahir | Head Of Quality Operations | Leadership |
Usman Zulqarnain | Head Of Sales & Marketing | Leadership |
Dr.tuaha Alam Siddiqui | Head Of Business Development | Leadership |
Zulfiqar Zaidi | Director Human Resources & Strategic Planning | Leadership |
Numan Nasir | Head Of Marketing | Leadership |
Ahsen Javed | Lead HR Business Partner | Leadership |
Farhan Hashmi | Associate Director Information Technology | Leadership |
Saima Hameed | Head Of Regulatory Affairs | Leadership |
Zainub Abbas | Director | Board & advisors |
Tausif Ahmad Khan | Chairman | Board & advisors |
Ghulam Hussain Khan | Director | Board & advisors |
Shazib Masud | Director | Board & advisors |
Romesh Elapata | Director | Board & advisors |
Anees Ahmed | Officer - OEE | Team |
Nimra W. | Executive Group Quality Compliance | Team |
Sibgha Hafeez | Lead Strategic Planning & Projects | Team |
Zainab Naveed Malik | Marketing Manager | Team |
8 more people are available in the full profile.
Complete people profiles for Highnoon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Highnoon
Highnoon is a publicly listed company on the PSX with ticker symbol HINOON in Pakistan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Jan 1995
- Listed onPSX: HINOON
- Listed entityHighnoon Laboratories Limited
- Exchange sectorHealth technology
- ISINPK0070701013
- Share price933.95 PKR (+0.52% on the day) · 2026-10-12
- Market capitalisation49,226,845,841.00 PKR
- Price to earnings12.5
- EPS (diluted, trailing year)74.76 PKR
- Dividend yield5.38%
- Volume (last session)6,219
Financials of Highnoon
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 27.71B PKR | 4.13B PKR | 6.81B PKR |
| 2024 | 24.64B PKR | 3.39B PKR | 5.39B PKR |
| 2023 | 19.77B PKR | 2.45B PKR | 3.70B PKR |
| 2022 | 15.82B PKR | 2.47B PKR | 3.47B PKR |
| 2021 | 13.00B PKR | 1.86B PKR | 2.55B PKR |
Detailed financial statements for Highnoon
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Highnoon
Highnoon operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Eurofins Scientific, WuXi AppTec, Ipsen, CHEPLAPHARM and ANI Pharmaceuticals, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| eurofins.com | 1987 | Luxembourg | – | – | Laboratory testing and contract research services are provided globally. | |
| wuxiapptec.com | 2000 | Shanghai, China | $40M | 1,681 | Provider of CRO and CDMO services | |
| ipsen.com | 1929 | – | – | 505 | Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes | |
| cheplapharm.com | 1998 | Mesekenhagen, Germany | – | 840 | Branded pharmaceutical products are developed, marketed, and distributed globally. | |
| anipharmaceuticals.com | 1996 | Baudette, United States | – | 600 | Branded and generic prescription drugs are developed, manufactured, and marketed. | |
| caidya.com | 2003 | Morrisville, United States | $373M | 351 | CRO focused on clinical development for phases II & III clinical trials and regulatory affair services | |
| rednucleus.com | 2014 | Yardley, United States | – | 176 | Advisory, scientific, and medical communications provided for pharmaceutical industry. | |
| aptar.com | 1992 | Crystal Lake, United States | – | 232 | Regulatory support, brand differentiation, and prototyping services are provided. | |
| aliadatx.com | 2021 | Boston, United States | $33M | – | Provider of drug research & development services for multiple therapeutic areas |
Detailed competitors of Highnoon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Highnoon
The website of Highnoon (highnoon-labs.com) receives about 680.7K visits a month and ranks #902,114 among all websites worldwide, #1,578 in Pharmacy.
- Monthly visits680.7K
▼ 6.7% vs previous month
- Unique visitors15.7K
per month
- Global rank#902,114
among all websites
- Category rank#1,578
Health · Pharmacy
- Bounce rate57%
- Pages per visit2.4
- Average visit25 sec
- DevicesDesktop 18% · Mobile 82%
Websites whose visitors overlap most with Highnoon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| falconebiz.com | 100% | 959.8K | #63,970 | View details | |
| tofler.in | 97% | 556K | #105,509 | View details | |
| zaubacorp.com | 96% | 4.9M | #12,689 | View details | |
| tracxn.com | 92% | 2.9M | #16,597 | View details | |
| indiafilings.com | 90% | 2.1M | #29,959 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Highnoon
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Highnoon
Complete news archive for Highnoon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Highnoon
10 companies that operate in the same segment as Highnoon (Rare Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing. | 2013 | Basel, Basel-stadt, Switzerland | USD 127 M | USD 37.31 M | 393 | |
Gene therapies for rare diseases are developed to treat patients. | 2020 | Columbus, Ohio, United States | USD 250 M | – | – | |
Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases | 2015 | Cambridge, Massachusetts, United States | USD 114.67 M | – | 45 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Therapies for gastrointestinal diseases are developed by Phathom Pharmaceuticals. | 2019 | Menlo Park, California, United States | USD 90 M | USD 175.11 M | 427 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Highnoon
Highnoon was founded in 1984.
Highnoon is headquartered in Lahore, Pakistan. It is registered at Lahore, Punjab, Pakistan.
Highnoon Laboratories Limited, based in Lahore, Pakistan, produces and markets pharmaceutical medicines across therapeutic areas like cardiology and gastroenterology. It engages in research and development, forms global alliances for innovation, and supports public health initiatives such as thalassemia aid. The company operates nationwide offices, donates medicines to vulnerable communities, and ensures quality manufacturing while expanding exports.
Highnoon's top competitors include WuXi AppTec, ANI Pharmaceuticals and Aptar.
Highnoon offers Feripro Capsule, Cardiology Products, and Gastroenterology Products.
Yes, Highnoon is publicly traded on PSX under the ticker symbol HINOON.
Highnoon operates through Highnoon Laboratories Limited.
The website of Highnoon receives about 681 thousand visits a month and ranks #902,114 among all websites worldwide.